Tumor-specific-antigen CD8 T (TSA-T) cells are appreciated as the primary drivers of antitumor immunity and responders to ICI therapy, as they can recognize and kill cancer cells expressing unique neoantigens41. This evidence concerns the gene CD8A and neoplasm.